A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208)

医学 吉西他滨 危险系数 佐剂 肝切除术 置信区间 胆道癌 内科学 化疗 辅助治疗 外科 胃肠病学 存活率 随机对照试验 胆道 切除术
作者
Shogo Kobayashi,Hiroaki Nagano,Akira Tomokuni,Kunihito Gotoh,Daisuke Sakai,Etsuro Hatano,Satoru Seo,Hiroaki Terajima,Yoichiro Uchida,Tetsuo Ajiki,Hironaga Satake,Keiko Kamei,Taiji Tohyama,Tetsuro Hirose,Iwao Ikai,Satoshi Morita,Tatsuya Ioka
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
卷期号:270 (2): 230-237 被引量:51
标识
DOI:10.1097/sla.0000000000002865
摘要

Objective: To evaluate each arm independently and compare adjuvant gemcitabine (GEM) and S-1 chemotherapy after major hepatectomy (hemihepatectomy or trisectionectomy) for biliary tract cancer (BTC). Background: Standardized adjuvant therapy is not performed after major hepatectomy for BTC, and we determined the recommended dose in the former study (KHBO1003). Methods: We performed a multicenter, randomized phase II study. The primary measure was 1-year recurrence-free survival (RFS); the secondary measures were other RFS, overall survival (OS), and others. The following 6-month adjuvant chemotherapy was administered within 12 weeks of R0/1: GEM (1000 mg/m 2 ) every 2 weeks; or S-1 (80 mg/m 2 /d) for 28 days every 6 weeks. Thirty-five patients were assigned to each arm (alpha error, 10%; beta error, 20%). Results: No patients were excluded for the per-protocol analysis. There were no statistically significant differences in the patient characteristics of the 2 arms. The 1-year RFS and 1-year OS rates of the GEM arm were 51.4% and 80.0%, respectively, whereas those of the S-1 group were 62.9% and 97.1%. The comparison of the 2 arms revealed that 2-year RFS rate, 1 and 2-year OS rates, and OS curve of the S-1 arm were superior to GEM. With regard to OS, the hazard ratio of the S-1 group was 0.477 (90% confidence interval 0.245–0.927). Conclusion: The comparison of the survival of the 2 groups revealed that adjuvant S-1 therapy may be superior to adjuvant GEM therapy after major hepatectomy for BTC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
九黎发布了新的文献求助50
刚刚
1秒前
huangdq6完成签到 ,获得积分10
2秒前
2秒前
大个应助Somogyis采纳,获得10
3秒前
大个应助科研通管家采纳,获得10
4秒前
胡二狗应助科研通管家采纳,获得10
4秒前
安安应助科研通管家采纳,获得10
4秒前
4秒前
4秒前
侠女发布了新的文献求助10
5秒前
溜溜球发布了新的文献求助10
5秒前
6秒前
mouxq发布了新的文献求助10
9秒前
10秒前
wmmm发布了新的文献求助30
10秒前
10秒前
10秒前
隐形曼青应助荣枫采纳,获得10
11秒前
11秒前
12秒前
13秒前
SGI发布了新的文献求助10
15秒前
花怜完成签到 ,获得积分10
15秒前
柯一一应助HEROTREE采纳,获得10
15秒前
15秒前
16秒前
雷家发布了新的文献求助10
16秒前
平淡的紫萱完成签到,获得积分20
16秒前
16秒前
麻小医发布了新的文献求助10
16秒前
17秒前
17秒前
顾矜应助SSS采纳,获得10
17秒前
所所应助nbbyysnbb采纳,获得10
18秒前
18秒前
18秒前
18秒前
hhw发布了新的文献求助10
18秒前
荣枫完成签到,获得积分10
19秒前
高分求助中
Востребованный временем 2500
Injection and Compression Molding Fundamentals 1000
Classics in Total Synthesis IV: New Targets, Strategies, Methods 1000
Hopemont Capacity Assessment Interview manual and scoring guide 650
Mantids of the euro-mediterranean area 600
The Oxford Handbook of Educational Psychology 600
Mantodea of the World: Species Catalog Andrew M 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 基因 遗传学 化学工程 复合材料 免疫学 物理化学 细胞生物学 催化作用 病理
热门帖子
关注 科研通微信公众号,转发送积分 3422593
求助须知:如何正确求助?哪些是违规求助? 3022859
关于积分的说明 8902954
捐赠科研通 2710376
什么是DOI,文献DOI怎么找? 1486403
科研通“疑难数据库(出版商)”最低求助积分说明 687061
邀请新用户注册赠送积分活动 682285